Literature DB >> 24475008

Urethrocutaneous fistula after use of Tegress bulking agent: Case report and review of the literature.

Anudeep Mukkamala1, Jerilyn M Latini1, Anne P Cameron1.   

Abstract

We report a case of a 68-year-old man who presented with a urethrocutaneous fistula after off-label use of Tegress (C. R. Bard, Inc., Murray Hill, NJ) Urethral Implant for post-prostatectomy incontinence. He was treated for prostate cancer with an open radical retropubic prostatectomy and adjuvant external beam radiation therapy. He was treated unsuccessfully for stress incontinence with a Tegress Urethral Implant and presented to our clinic initially with extrusion of the material urethrally. Four years later he re-presented with a large bullous skin lesion on his suprapubic area. Contrast-enhanced magnetic resonance imaging and retrograde urethral cystogram demonstrated a urethrocutaneous fistula. Subsequent cystoscopy revealed the calcified extruded material in the same location as the site of Tegress injection. The patient underwent simple cystectomy with ileal diversion. He recovered well postoperatively. This appears to be the first reported case of urethrocutaneous fistula after use of a Tegress Urethral Implant for post-prostatectomy stress urinary incontinence.

Entities:  

Year:  2013        PMID: 24475008      PMCID: PMC3879730          DOI: 10.5489/cuaj.481

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  14 in total

1.  Urethrocutaneous fistula as a severe complication of treatment for priapism.

Authors:  S De Stefani; G Savoca; S Ciampalini; S Stener; I GattucCio; E Belgrano
Journal:  BJU Int       Date:  2001-10       Impact factor: 5.588

2.  Tegresstrade mark Urethral Implant Phase III Clinical Experience and Product Uniqueness.

Authors:  Roger R Dmochowski
Journal:  Rev Urol       Date:  2005

3.  Randomized controlled multisite trial of injected bulking agents for women with intrinsic sphincter deficiency: mid-urethral injection of Zuidex via the Implacer versus proximal urethral injection of Contigen cystoscopically.

Authors:  Deborah Lightner; Eric Rovner; Jacques Corcos; Christopher Payne; Linda Brubaker; Harold Drutz; Gary Steinhoff
Journal:  Urology       Date:  2009-08-05       Impact factor: 2.649

4.  Cystoscopic injections of dextranomer hyaluronic acid into proximal urethra for urethral incompetence: efficacy and adverse outcomes.

Authors:  Deborah J Lightner; Janelle Fox; Christopher Klingele
Journal:  Urology       Date:  2010-03-17       Impact factor: 2.649

5.  Giant prostatic urethral calculus associated with urethrocutaneous fistula.

Authors:  Mustafa Kaplan; Irfan H Atakan; Esat Kaya; Tevfik Aktoz; Osman Inci
Journal:  Int J Urol       Date:  2006-05       Impact factor: 3.369

Review 6.  Current status of genitourinary fistula.

Authors:  R A Lee; R E Symmonds; T J Williams
Journal:  Obstet Gynecol       Date:  1988-09       Impact factor: 7.661

7.  Ethylene vinyl alcohol copolymer erosions after use as a urethral bulking agent.

Authors:  Elisabeth A Erekson; Vivian W Sung; Charles R Rardin; Deborah L Myers
Journal:  Obstet Gynecol       Date:  2007-02       Impact factor: 7.661

8.  The safety and efficacy of ethylene vinyl alcohol copolymer as an intra-urethral bulking agent in women with intrinsic urethral deficiency.

Authors:  Eric Hurtado; Rebecca McCrery; Rodney Appell
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-11-14

9.  Long-term results and patients' satisfaction after transurethral ethylene vinyl alcohol (Tegress) injections: a two-centre study.

Authors:  Annette Kuhn; Werner Stadlmayr; Amara Sohail; Ash Monga
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2007-10-23

10.  The late occurrence of urinary tract damage in patients successfully treated by radiotherapy for cervical carcinoma.

Authors:  J Zoubek; E J McGuire; F Noll; J O DeLancey
Journal:  J Urol       Date:  1989-06       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.